Skip to main content
KYORIN Pharmaceutical Co., Ltd. logo

KYORIN Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 4569 ISIN · JP3247090008 T Manufacturing
Open in API
Filings indexed 58 across all filing types
Latest filing 2023-11-14 Interim / Quarterly Rep…
Country JP Japan
Listing T 4569

About KYORIN Pharmaceutical Co., Ltd.

https://www.kyorin-pharm.co.jp/en/

KYORIN Pharmaceutical Co., Ltd. is a research-based pharmaceutical company engaged in the research, development, manufacturing, and sale of prescription (ethical) and generic drugs. The company's commercial and R&D activities are focused on key therapeutic areas, including respiratory medicine, urology, otolaryngology (ENT), and inflammatory bowel disease (IBD). Through its subsidiaries, such as KYORIN Rimedio Co., Ltd., it also handles the manufacturing and distribution of generic medicines. The company is committed to providing a stable supply of high-quality pharmaceutical products to medical institutions and patients.

Recent filings

Filing Released Lang Actions
四半期報告書－第66期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report
2023-11-14 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is filed under the Financial Instruments and Exchange Act Article 24-4-8. It serves as an officer certification regarding the accuracy of a quarterly report, rather than the quarterly report itself. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS). Q1 2023
2023-08-09 Japanese
四半期報告書－第66期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report
2023-08-09 Japanese
内部統制報告書－第65期(2022/04/01－2023/03/31)
Governance Information Classification · 1% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法) in Japan. This type of report is a mandatory regulatory filing that assesses the effectiveness of a company's internal controls over financial reporting. Since it is a specific regulatory requirement distinct from a full Annual Report (10-K) or an Audit Report (AR), and does not fit into the other specific categories provided, it is classified as a Regulatory Filing.
2023-06-26 Japanese
確認書
Regulatory Filings
2023-06-26 Japanese
有価証券報告書－第65期(2022/04/01－2023/03/31)
Annual Report Classification · 1% confidence The document is a 'Yuka Shoken Hokokusho' (Annual Securities Report), which is the Japanese equivalent of a 10-K. It contains comprehensive financial data, including consolidated and non-consolidated financial indicators, balance sheets, and management information for the fiscal year ending March 31, 2023. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2023
2023-06-26 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.